--- schema_version: "secwatch.filing_event.v1" accession: "0001140361-23-041917" form_type: "8-K" ticker: null cik: "0001822711" company_name: "PARDES BIOSCIENCES, INC." filed_at: "2023-08-31T23:59:59+00:00" generated_at: "2026-06-11T01:25:00.821698+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.9 calibrated_materiality_score: 0.9 confidence: "high" source: SEC EDGAR --- # Pardes Biosciences acquired by Foresite Capital affiliate for $2.13/share plus CVR; delisted from Nasdaq ## Summary - Tender offer expired Aug 30, 2023; 37,836,066 shares (~60.9% of outstanding) validly tendered. - Shareholders received $2.13 cash per share plus a non-tradeable CVR linked to future monetization of COVID-19 antiviral assets. - After the tender close, Merger Sub merged with Pardes; company became wholly owned subsidiary of MediPacific (Foresite Capital). - All shares ceased trading on Nasdaq prior to Aug 31, 2023; deregistration intended. - Board of directors resigned; new directors from Merger Sub include James B. Tananbaum and Dennis D. Ryan. ## SEC filing metadata - accession: 0001140361-23-041917 - form_type: 8-K - cik: 0001822711 - company_name: PARDES BIOSCIENCES, INC. - filed_at: 2023-08-31T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.9 - calibrated_materiality_score: 0.9 - confidence: high - sec_items: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/brhc20058194_8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001140361-23-041917 - JSON: https://secwatch.observer/filing/0001140361-23-041917.json - Plain text: https://secwatch.observer/filing/0001140361-23-041917.txt ## Key facts - Executive change James B. Tananbaum was appointed as Director, President and Chief Executive Officer at PARDES BIOSCIENCES, INC.. - Action: appointed - Role: Director, President and Chief Executive Officer source text: The directors and officers of Merger Sub immediately prior to the Effective Time were James B. Tananbaum, Director, President and Chief Executive Officer, and Dennis D. Ryan, director, Chief Financial Officer and Secretary. evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Deborah M. Autor resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Mark Auerbach resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Dennis D. Ryan was appointed as Director, Chief Financial Officer and Secretary at PARDES BIOSCIENCES, INC.. - Action: appointed - Role: Director, Chief Financial Officer and Secretary source text: The directors and officers of Merger Sub immediately prior to the Effective Time were James B. Tananbaum, Director, President and Chief Executive Officer, and Dennis D. Ryan, director, Chief Financial Officer and Secretary. evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Michael Varney resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change John C. Pottage Jr. resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Laurie Smaldone Alsup resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Laura J. Hamill resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Thomas G. Wiggans resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change J. Jay Lobell resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Executive change Uri A. Lopatin resigned as Director at PARDES BIOSCIENCES, INC.. - Action: resigned - Role: Director source text: each of Thomas G. Wiggans, Uri A. Lopatin, M.D, Mark Auerbach, Deborah M. Autor, J.D., Laura J. Hamill, J. Jay Lobell, John C. Pottage Jr., M.D., Laurie Smaldone Alsup, M.D. and Michael Varney resigned from the board of directors of the Company evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Governance Changes PARDES BIOSCIENCES, INC.: The bylaws were amended and restated in their entirety (effective 2023-08-31). - Change: bylaw amendment - Effective: 2023-08-31 source text: on August 31, 2023, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, copies of which are attached to this Current Report on Form 8-K as Exhibit 3.1 and Exhibit 3.2, respectively. evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - Governance Changes PARDES BIOSCIENCES, INC.: The certificate of incorporation was amended and restated in its entirety (effective 2023-08-31). - Change: charter amendment - Effective: 2023-08-31 source text: on August 31, 2023, the Company’s certificate of incorporation and bylaws were amended and restated in their entirety, copies of which are attached to this Current Report on Form 8-K as Exhibit 3.1 and Exhibit 3.2, respectively. evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm - M&A Transactions PARDES BIOSCIENCES, INC. underwent a change of control involving MediPacific, Inc., MediPacific Sub, Inc. for the Offer Price (i) $2.13 per share of Common Stock (the "Cash Amount") and (ii) one contingent value right (a "CVR") (closed 2023-08-31). - Action: change of control - Counterparty: MediPacific, Inc., MediPacific Sub, Inc. - Consideration: the Offer Price (i) $2.13 per share of Common Stock (the "Cash Amount") and (ii) one contingent value right (a "CVR") - Closing: 2023-08-31 source text: Merger Sub commenced a tender offer to purchase all of the C ompany’s outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), in exchange for (i) $2.13 per share of Common Stock (the “Cash Amount”) and (ii) one contingent value right (a “CVR”) associated with any future monetization of the Company’s antiviral drug development evidence_url: https://www.sec.gov/Archives/edgar/data/1822711/000114036123041917/0001140361-23-041917-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.